1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease

Patent metadata

Field	Value
Publication number	US-9611230-B2
Application number	US-57719105-A
Country	US
Kind code	B2
Filing date	Oct 13, 2005
Priority date	Oct 13, 2004
Publication date	Apr 4, 2017
Grant date	Apr 4, 2017

Abstract

The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

First claim

What is claimed:

1. A compound of Formula 1-A:

wherein:
R 3 is absent;
W is selected from the group consisting of:

wherein when W is selected from the group consisting of:

then

 shown in Formula 1-A is in the meta or para position; and
wherein when W is selected from the group consisting of

then

 shown in Formula 1-A is in the meta position;
and a pharmaceutically acceptable salt of said compound of Formula 1-A, wherein * indicates the only bond of attachment for W, and wherein said bond of attachment is a direct bond of attachment.

2. A compound selected from the group consisting of:

and a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein said compound is selected from the group consisting of:

Assignees

• Almstead Neil G
• Chen Guangming
• Karp Gary M
• Welch Ellen
• Wilde Richard
• Campbell Jeffrey A
• Ptc Therapeutics Inc

Inventors

• Almstead Neil G
• Chen Guangming
• Karp Gary M
• Welch Ellen
• Wilde Richard
• Campbell Jeffrey A

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title